Fda grants orphan drug designation for inflazome’s inzomelid for the treatment of cryopyrin-associated periodic syndromes (caps)

Inflazome (inflazome.com), the pioneering inflammasome biotech company developing multiple drugs that stop harmful inflammation, today announces that

MDGL Ratings Summary

MDGL Quant Ranking